Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design von Jain, Raksha, Magaret, Amalia, Vu, Phuong T, VanDalfsen, Jill M, Keller, Ashley, Wilson, Alexandra, Putman, Melissa S, Mayer-Hamblett, Nicole, Esther Jr, Charles R, Taylor-Cousar, Jennifer L

Volltext

Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients von Moheet, Amir, Beisang, Daniel, Zhang, Lin, Sagel, Scott D., VanDalfsen, Jill M., Heltshe, Sonya L., Frederick, Carla, Mann, Michelle, Antos, Nicholas, Billings, Joanne, Rowe, Steven M., Moran, Antoinette

Volltext

Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis The SIMPLIFY Clinical Trial Study Design von Mayer-Hamblett, Nicole, Nichols, David P., Odem-Davis, Katherine, Riekert, Kristin A., Sawicki, Greg S., Donaldson, Scott H., Ratjen, Felix, Konstan, Michael W., Simon, Noah, Rosenbluth, Daniel B., Retsch-Bogart, George, Clancy, John P., VanDalfsen, Jill M., Buckingham, Rachael, Gifford, Alex H.

Volltext

PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy von Nichols, Dave P., Donaldson, Scott H., Frederick, Carla A., Freedman, Steven D., Gelfond, Daniel, Hoffman, Lucas R., Kelly, Andrea, Narkewicz, Michael R., Pittman, Jessica E., Ratjen, Felix, Sagel, Scott D., Rosenfeld, Margaret, Schwarzenberg, Sarah Jane, Singh, Pradeep K., Solomon, George M., Stalvey, Michael S., Kirby, Shannon, VanDalfsen, Jill M., Clancy, John P., Rowe, Steven M.

Volltext

Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial von Muhlebach, Marianne Sponer, Beckett, Valeria, Popowitch, Elena, Miller, Melissa B, Baines, Arthur, Mayer-Hamblett, Nicole, Zemanick, Edith T, Hoover, Wynton C, VanDalfsen, Jill M, Campbell, Preston, Goss, Christopher H

Volltext

The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network von Pearson, Kelsie, Mayer-Hamblett, Nicole, Goss, Christopher H., Retsch-Bogart, George Z., VanDalfsen, Jill M., Burks, Patricia, Rosenbluth, Daniel, Clancy, John Paul, Hoffman, Amy, Nichols, David P.

Volltext

Prospective evaluation of nontuberculous mycobacteria disease in cystic fibrosis: The design of the PREDICT study von Martiniano, Stacey L., Caceres, Silvia M., Poch, Katie, Rysavy, Noel M., Lovell, Valerie K., Armantrout, Emily, Jones, Marion, Anthony, Margaret, Keck, Allison, Nichols, David P., Vandalfsen, Jill M., Sagel, Scott D., Wagner, Brandie, Xie, Jing, Weaver, Katie, Heltshe, Sonya L., Daley, Charles L., Davidson, Rebecca M., Nick, Jerry A.

Volltext

Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR A Clinical Trial von Sagel, Scott D., Khan, Umer, Heltshe, Sonya L., Clancy, John P., Borowitz, Drucy, Gelfond, Daniel, Donaldson, Scott H., Moran, Antoinette, Ratjen, Felix, VanDalfsen, Jill M., Rowe, Steven M.

Volltext

Lumacaf tor/ivacaf tor therapy fails to increase insulin secretion in F508del/F508del CF patients von Moheet, Amir, Beisang, Daniel, Zhang, Lin, Sagel, Scott D., VanDalfsen, Jill M., Heltshe, Sonya L., Frederick, Carla, Mann, Michelle, Antos, Nicholas, Billings, Joanne, Rowe, Steven M., Moran, Antoinette

Volltext

Microbiologic Efficacy of early MRSA treatment in cystic fibrosis in a randomized controlled trial von Muhlebach, Marianne Sponer, Thompson, Valeria, Popowitch, Elena, Miller, Melissa B., Baines, Arthur, Mayer-Hamblett, Nicole, Zemanick, Edith T, Hoover, Wynton C, VanDalfsen, Jill M., Campbell, Preston, Goss, Christopher H

Volltext

Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations von Guimbellot, Jennifer, Solomon, George M., Baines, Arthur, Heltshe, Sonya L., VanDalfsen, Jill, Joseloff, Elizabeth, Sagel, Scott D., Rowe, Steven M.

Volltext